Anti-AKT1 (pS473) + AKT2 (pS474) + AKT3 (pS472) antibody [EPR18853] (Ab192623)
PKB, RAC, AKT1, RAC-alpha serine/threonine-protein kinase, Protein kinase B, Protein kinase B alpha, Proto-oncogene c-Akt, RAC-PK-alpha, PKB alpha, RAC-beta serine/threonine-protein kinase, Protein kinase Akt-2, Protein kinase B beta, RAC protein kinase beta, PKB beta, RAC-PK-beta, AKT2, PKBG, AKT3, RAC-gamma serine/threonine-protein kinase, Protein kinase Akt-3, Protein kinase B gamma, RAC-PK-gamma, STK-2, PKB gamma
详细信息
背景信息
What is this antibody validated in? Anti-AKT1 (pS473) + AKT2 (pS474) + AKT3 (pS472) antibody [EPR18853] (ab192623) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP), Immunocytochemistry/immunofluorescence (ICC/IF), Dot Blot in Human, Mouse, Rat samples. What is the molecular weight of AKT1? Anti-AKT1 (pS473) + AKT2 (pS474) + AKT3 (pS472) [EPR18853] (ab192623) specifically detects a band for AKT1 (UniProt: Q9Y243) at a molecular weight of 56kDa. Trusted by the scientific community Anti-AKT1 (pS473) + AKT2 (pS474) + AKT3 (pS472) [EPR18853] (ab192623) was first used in a scientific publication in 2016 and has been cited over 60 times in peer-reviewed journals. Other related products We have a range of other formats of antibody clone [EPR18853] also available for your convenience: ab192623, Carrier free - ab222489, Carrier free - ab272367, Carrier free - ab285140 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.
文献引用 (132)
INHBA, regulated by C/EBPβ, induces M2 macrophage polarization to promote tumor metastasis and growth via activating the PI3K/AKT pathway in gastric cancer.
INHBA 受 C/EBPβ 调控,诱导 M2 巨噬细胞极化,通过激活胃癌中的 PI3K/AKT 通路促进肿瘤转移和生长。
CircFAM120B promotes prostate cancer progression through miR-1182 inhibition and FBXO17-mediated AKT activation.
CircFAM120B 通过抑制 miR-1182 和 FBXO17 介导的 AKT 激活促进前列腺癌的进展。
TMB-related immune gene PAEP influences clear cell renal cell carcinoma progression and prognosis
TMB相关免疫基因PAEP影响透明细胞肾细胞癌的进展和预后
Inhibition of ARH2 by pH/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy.
利用 pH/ROS 响应纳米系统抑制 ARH2 以改善肺腺癌免疫化疗
Nanozyme eye drops for retinal barrier penetration and vasculopathy repair.
用于视网膜屏障穿透和血管病变修复的纳米酶滴眼液。
Natural killer cell-specific chimeric antigen receptor enhances CAR NK cell functions and anti-tumor activity
自然杀伤细胞特异性嵌合抗原受体增强CAR NK细胞功能和抗肿瘤活性
Targeting mitochondrial complex I of CD177+ neutrophils alleviates lung ischemia-reperfusion injury
靶向CD177+中性粒细胞的线粒体复合物I可减轻肺缺血再灌注损伤。
Periodontitis Accelerates Progression of Heart Failure With Preserved Ejection Fraction in Mice.
牙周炎加速小鼠射血分数保留型心力衰竭的进展
The molecular mechanism of ginsenoside Rh2 and its octyl ester derivative on anti-angiogenesis in cancer treatment: The battle between PI3K and ROS
人参皂苷Rh2及其辛酯衍生物抗肿瘤血管生成分子机制:PI3K与ROS之战
Isolation of Proteins on Chromatin Reveals Signaling Pathway-Dependent Alterations in the DNA-Bound Proteome
染色质上蛋白质的分离揭示了 DNA 结合蛋白质组中信号通路依赖性改变
- 1
- 2
- 3
- 4
- 5
- 6
- 14